The Role of Oncolytic Viruses in the Treatment of Melanoma

Randomized, Open-Label Phase II Study Evaluating the Efficacy and Safety of Talimogene Laherparepvec in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced, Unresectable Melanoma

(2018) Jason Chesney et al.   JOURNAL OF CLINICAL ONCOLOGY

Defining the role of the tumor vasculature in antitumor immunity and immunotherapy

(2018) Marco B. Schaaf et al.   Cell Death & Disease

Designing and building oncolytic viruses

(2017) Justin Maroun et al.   Future Virology

Review: Oncolytic virotherapy, updates and future directions

(2017) Christos Fountzilas et al.   Oncotarget

Phase Ib study of intratumoral oncolytic coxsackievirus A21 (CVA21) and pembrolizumab in subjects with advanced melanoma

(2016) H.L. Kaufman et al.   ANNALS OF ONCOLOGY

Long-term treatment with the oncolytic ECHO-7 virus Rigvir of a melanoma stage IV M1c patient, a small cell lung cancer stage IIIA patient, and a histiocytic sarcoma stage IV patient-three case reports

(2016) Pēteris Alberts et al.   APMIS

Talimogene Laherparepvec in Combination With Ipilimumab in Previously Untreated, Unresectable Stage IIIB-IV Melanoma

(2016) Igor Puzanov et al.   JOURNAL OF CLINICAL ONCOLOGY

Systemic versus local responses in melanoma patients treated with talimogene laherparepvec from a multi-institutional phase II study

(2016) Howard L. Kaufman et al.   Journal for ImmunoTherapy of Cancer

Oncolytic Viruses: Therapeutics With an Identity Crisis

(2016) Caroline J. Breitbach et al.   EBioMedicine

VEGF-Mediated Induction of PRD1-BF1/Blimp1 Expression Sensitizes Tumor Vasculature to Oncolytic Virus Infection

(2015) Rozanne Arulanandam et al.   CANCER CELL

Oncolytic viruses: focusing on the tumor microenvironment

(2015) C R de Vries et al.   CANCER GENE THERAPY

Oncolytic Virus Immunotherapy for Melanoma

(2015) Neal Dharmadhikari et al.   CURRENT TREATMENT OPTIONS IN ONCOLOGY

Treatment of melanoma with a serotype 5/3 chimeric oncolytic adenovirus coding for GM-CSF: Resultsin vitro, in rodents and in humans

(2015) Simona Bramante et al.   INTERNATIONAL JOURNAL OF CANCER

Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma

(2015) Robert H.I. Andtbacka et al.   JOURNAL OF CLINICAL ONCOLOGY

Adapted ECHO-7 virus Rigvir immunotherapy (oncolytic virotherapy) prolongs survival in melanoma patients after surgical excision of the tumour in a retrospective study

(2015) Simona Doniņa et al.   MELANOMA RESEARCH

Oncolytic viruses: a new class of immunotherapy drugs

(2015) Howard L. Kaufman et al.   NATURE REVIEWS DRUG DISCOVERY

Recombinant Newcastle Disease virus Expressing IL15 Demonstrates Promising Antitumor Efficiency in Melanoma Model

(2015) Zeshan Niu et al.   TECHNOLOGY IN CANCER RESEARCH & TREATMENT

A Phase I, multicenter, open-label trial to evaluate the safety of talimogene laherparepvec (T-VEC) injected into liver tumors

(2015) J Randolph Hecht et al.   Journal for ImmunoTherapy of Cancer

Regulation of dendritic cell development by GM-CSF: molecular control and implications for immune homeostasis and therapy

(2012) L. van de Laar et al.   BLOOD

Chemokine-based immunotherapy: delivery systems and combination therapies

(2012) Elham Mohit et al.   Immunotherapy

REO-001: A phase I trial of percutaneous intralesional administration of reovirus type 3 dearing (Reolysin®) in patients with advanced solid tumors

(2012) Don G. Morris et al.   INVESTIGATIONAL NEW DRUGS

The extracellular matrix: A dynamic niche in cancer progression

(2012) Pengfei Lu et al.   JOURNAL OF CELL BIOLOGY

Phase II Trial of Intravenous Administration of Reolysin® (Reovirus Serotype-3-dearing Strain) in Patients with Metastatic Melanoma

(2012) Evanthia Galanis et al.   MOLECULAR THERAPY

Impact of novel oncolytic virus HF10 on cellular components of the tumor microenviroment in patients with recurrent breast cancer

(2011) T T Sahin et al.   CANCER GENE THERAPY

Armed and targeted measles virus for chemovirotherapy of pancreatic cancer

(2011) S Bossow et al.   CANCER GENE THERAPY

Oncolytic Specificity of Newcastle Disease Virus Is Mediated by Selectivity for Apoptosis-Resistant Cells

(2011) M. Mansour et al.   JOURNAL OF VIROLOGY

Oncolysis of malignant human melanoma tumors by Coxsackieviruses A13, A15 and A18

(2011) Gough G Au et al.   Virology Journal

A phase I dose-escalation clinical trial of intraoperative direct intratumoral injection of HF10 oncolytic virus in non-resectable patients with advanced pancreatic cancer

(2010) A Nakao et al.   CANCER GENE THERAPY

Hyaluronidase Expression by an Oncolytic Adenovirus Enhances Its Intratumoral Spread and Suppresses Tumor Growth

(2010) Sonia Guedan et al.   MOLECULAR THERAPY

Local and Distant Immunity Induced by Intralesional Vaccination with an Oncolytic Herpes Virus Encoding GM-CSF in Patients with Stage IIIc and IV Melanoma

(2009) Howard L. Kaufman et al.   ANNALS OF SURGICAL ONCOLOGY

Genetically engineered Newcastle disease virus for malignant melanoma therapy

(2009) D Zamarin et al.   GENE THERAPY

The Case of Oncolytic Viruses Versus the Immune System: Waiting on the Judgment of Solomon

(2009) Robin J. Prestwich et al.   HUMAN GENE THERAPY

Phase II Clinical Trial of a Granulocyte-Macrophage Colony-Stimulating Factor–Encoding, Second-Generation Oncolytic Herpesvirus in Patients With Unresectable Metastatic Melanoma

(2009) Neil N. Senzer et al.   JOURNAL OF CLINICAL ONCOLOGY

Intranodal Immunization With a Vaccinia Virus Encoding Multiple Antigenic Epitopes and Costimulatory Molecules in Metastatic Melanoma

(2009) Michel Adamina et al.   MOLECULAR THERAPY

Intelligent Design: Combination Therapy With Oncolytic Viruses

(2009) Kathryn Ottolino-Perry et al.   MOLECULAR THERAPY

A Phase I Study of Intravenous Oncolytic Reovirus Type 3 Dearing in Patients with Advanced Cancer

(2008) L. Vidal et al.   CLINICAL CANCER RESEARCH

Inflammatory tumour cell killing by oncolytic reovirus for the treatment of melanoma

(2008) F Errington et al.   GENE THERAPY

Oncolytic virotherapy for malignant melanoma with herpes simplex virus type 1 mutant HF10

(2008) Daisuke Watanabe et al.   JOURNAL OF DERMATOLOGICAL SCIENCE